Target intelligence / Profile preview

HIV-1 envelope glycoprotein gp120 V3 loop (gp120 V3 loop)

Target
gp120 V3 loop
Molecular classification
Viral glycoprotein, Other
01

Overview

The HIV-1 envelope glycoprotein gp120 V3 loop (third variable loop) is a critical region of the viral envelope spike that plays a pivotal role in viral entry and pathogenesis. It is responsible for determining viral tropism by interacting with host cell co-receptors, primarily CCR5 or CXCR4, following the initial binding of gp120 to the CD4 receptor. Because of its essential role in infection, the V3 loop is a major target for the host humoral immune response and is often referred to as the principal neutralizing determinant of HIV-1. However, the high sequence variability of this region and its conformational occlusion within the pre-fusion envelope trimer present significant challenges for vaccine design and therapeutic targeting.

In recent years, the discovery of second-generation broadly neutralizing antibodies (bNAbs) has revitalized interest in the V3 loop as a therapeutic target. These bNAbs, such as zinlirvimab (10-1074-LS) and PGT121, target conserved peptide motifs and associated glycans (such as the N332 glycan supersite) at the base of the V3 loop. By binding to these sites, the antibodies prevent the conformational changes required for co-receptor engagement, thereby blocking viral entry into host CD4+ T cells. Clinical development of these bNAbs, often in combination with other long-acting antiretrovirals like lenacapavir, represents a promising strategy for long-acting HIV-1 treatment and prevention.

Other names
HIV-1 gp120 V3 regionHIV-1 gp120 third variable loopgp120 V3 loopV3 loop of gp120HIV-1 gp120 V3 domainPrincipal neutralizing determinant of HIV-1V3 glycan supersiteV3 glycan patch
02

Mechanism of action

Broadly neutralizing antibodies (bNAbs) bind to the V3 loop or its associated glycans (such as the N332 glycan supersite) on the HIV-1 gp120 envelope glycoprotein. This binding physically blocks the interaction of gp120 with host cell co-receptors (CCR5 or CXCR4) and prevents viral entry and fusion into host CD4+ T cells.

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Rapid emergence of viral escape mutantsHigh sequence variability of the V3 loop across different HIV-1 cladesConformational masking of the V3 loop in the closed pre-fusion Env trimerInfusion-related reactions
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

HIV-1 viral loadCD4+ T-cell countV3 loop sequence sensitivityN332 glycosylation site presence

Beyond the preview

Go deeper on HIV-1 envelope glycoprotein gp120 V3 loop (gp120 V3 loop).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 envelope glycoprotein gp120 V3 loop (gp120 V3 loop).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call